Protara Net Interest Income from 2010 to 2026
| TARA Stock | USD 7.08 0.08 1.14% |
Net Interest Income | First Reported 2019-06-30 | Previous Quarter 1.6 M | Current Value 1.5 M | Quarterly Volatility 556.3 K |
Check Protara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Protara Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 400.9 K, Other Operating Expenses of 32.9 M or Research Development of 38.3 M, as well as many indicators such as Price To Sales Ratio of 36.82, Dividend Yield of 0.0 or PTB Ratio of 0.71. Protara financial statements analysis is a perfect complement when working with Protara Therapeutics Valuation or Volatility modules.
Protara | Net Interest Income | Build AI portfolio with Protara Stock |
Analyzing Protara Therapeutics's Net Interest Income over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Interest Income has evolved provides context for assessing Protara Therapeutics's current valuation and future prospects.
Latest Protara Therapeutics' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Protara Therapeutics over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Protara Therapeutics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Protara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Protara Net Interest Income Regression Statistics
| Arithmetic Mean | 1,366,545 | |
| Geometric Mean | 785,642 | |
| Coefficient Of Variation | 122.58 | |
| Mean Deviation | 1,330,480 | |
| Median | 466,000 | |
| Standard Deviation | 1,675,139 | |
| Sample Variance | 2.8T | |
| Range | 4.8M | |
| R-Value | 0.76 | |
| Mean Square Error | 1.3T | |
| R-Squared | 0.57 | |
| Significance | 0.0005 | |
| Slope | 250,505 | |
| Total Sum of Squares | 44.9T |
Protara Net Interest Income History
About Protara Therapeutics Financial Statements
Protara Therapeutics stakeholders use historical fundamental indicators, such as Protara Therapeutics' Net Interest Income, to determine how well the company is positioned to perform in the future. Although Protara Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Protara Therapeutics' assets and liabilities are reflected in the revenues and expenses on Protara Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Protara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 4.8 M | 5 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Protara Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Protara Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Protara Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Protara Therapeutics Stock:Check out the analysis of Protara Therapeutics Correlation against competitors. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Protara Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Protara Therapeutics requires distinguishing between market price and book value, where the latter reflects Protara's accounting equity. The concept of intrinsic value—what Protara Therapeutics' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Protara Therapeutics' price substantially above or below its fundamental value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Protara Therapeutics' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.